Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia|
|Citation:||Internal Medicine Journal, 2010; 40(2):139-149|
|Publisher:||Blackwell Publishing Asia|
|W. Connell, J. M. Andrews, S. Brown and M. Sparrow|
|Abstract:||Anti-tumour necrosis factor (TNF) therapy is an effective but expensive option for treating inflammatory bowel disease (IBD). Its use is generally reserved for patients with severe refractory disease, often involving long-term administration. Anti-TNF therapy has the potential to be associated with various adverse effects, such as infection, malignancy and immunogenicity. Clinicians and patients should be familiar with these possibilities and adopt appropriate precautions prior to and during treatment to minimize risk. Guidelines have been developed for Australian prescribers intending to use anti-TNF therapy in IBD by a Working Party commissioned by IBD-Australia, a Special Interest Group affiliated with the Gastroenterology Society of Australia.|
anti TNF therapy
|Rights:||© 2010 The Authors. Journal compilation © 2010 Royal Australasian College of Physicians|
|Appears in Collections:||Aurora harvest|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.